Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-Year outcome

Retina

Volumn 26, Issue 6, 2006, Pages 602-612

  Ruiz Moreno, José Ma ^a,b,d   Montero, Javier A ^b   Barile, Stefano ^b   Zarbin, Marco A ^c,e  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Vitreo Retinal Unit ^*  (Spain)

^c INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e GENENTECH INC   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Intravitreous triamcinolone; Photodynamic therapy

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BIMATOPROST; CARTEOLOL; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CATARACT; CHOROID VASCULARIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; VISUAL ACUITY; WILCOXON SIGNED RANKS TEST; DRUG COMBINATION; DRUG EFFECT; EXUDATE; FLUORESCENCE ANGIOGRAPHY; INJECTION; MIDDLE AGED; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; VITREOUS BODY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETREATMENT; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 33747341641     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200607000-00003     Document Type: Article

References (30)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch Ophthalmol 2002;120:1307-1314.
2. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404.
3. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of pre-retinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
4. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
5. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
6. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial for a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch Ophthalmol 2003;121:667-673.
7. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-468.
8. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
9. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
10. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.
11. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
12. Ruiz-Moreno JM, Montero JA, Artola A, Barile S. Anterior chamber transit of triamcinolone after intravitreal injection. Arch Ophthalmol 2005;123:129-130.
13. Chylack LT, Wolfe JK, Singer DM, et al. The lens opacities classification system III. Arch Ophthalmol 1993;111:831-836.
14. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci 2002;43:830-841.
15. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995;113:810-818.
16. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059.
17. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529.
18. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
19. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
20. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
21. - production by polymorphonuclear leukocytes of patients receiving corticosteroids. J Clin Lab Immunol 1990;33:117-123.
22. Dweik RA, Lewis M, Kavuru M, et al. Inhaled corticosteroids and beta-agonist inhibit oxidant production by bronchoalveolar lavage cells from normal volunteers in vivo. Immunopharmacology 1997;37:163-166.
23. Majori M, Vachier I, Godard P, et al. Superoxide anion production by monocytes of corticosteroid-treated asthmatic patients. Eur Respir J 1998;11:133-138.
24. Weishaupt K, Gomer C, Dougherty T. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of murine tumor. Cancer Res 1976;36:2326-2329.
25. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-432.
26. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-143.
27. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
28. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
29. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
30. Masson JO, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 2004;24:900-904.